Form 4 for IMMX Immix Biopharma, Inc.
Accepted 2023-09-15 00:00:00 ET · period of report 2023-09-14 · accession 0001493152-23-032829 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-09-15 | 2023-09-14 | IMMX | Ng Carey | Dir | P - Purchase | $2.58 | +10.0K | 10.0K | New | +$25.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-14 | P | A | 10,000 | $2.58 | 10,000 | D | — | — | (F1) This transaction was executed in multiple trades at prices ranging from $2.51 to $2.60, inclusive. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |